Powered by

-ATARA BIOTHERAPEUTICS ANNOUNCES COLLABORATOR PRESENTATION UPDATING POSITIVE PHASE 1 CLINICAL RESULTS FOR A MESOTHELIN-TARGETED CAR T IMMUNOTHERAPY

Jun 05, 2019 - ENP Newswire

SOUTH SAN FRANCISCO - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company's collaborators at Memorial Sloan Kettering Cancer Center (MSK), Prasad S. Adusumilli, M.D. and Michel Sadelain, M.D., Ph.D., presented an update on encouraging results from an ongoing MSK investigator-sponsored Phase 1 clinical study (NCT02414269) of...